O
PFE icon

OrbiMed’s Pfizer PFE Stock Holding History

OrbiMed’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-263,500
Closed -$10.8M – 132
2019
Q2 		$10.8M Buy
+263,500
New +$10.5M 0.17% 92

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OrbiMed's PFE Position: Q2 2026 in Review

OrbiMed sold out of Pfizer (PFE) in Q2 2026, closing a stake of 1,946,500 shares — an estimated $54.7M sold.

OrbiMed first reported a position in PFE in Q2 2013 and held it in 33 quarters. The position peaked at $202M in Q1 2022. 2,831 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • OrbiMed reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
  • OrbiMed sold 1,946,500 Pfizer shares in Q2 2026, an estimated $54.7M.
  • OrbiMed first reported a position in Pfizer in Q2 2013 and held it in 33 quarters.
  • OrbiMed's Pfizer position peaked at $202M in Q1 2022.
  • 2,831 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.